CFRX News and Press, ContraFect Corporation From 03/17/21

ContraFect (CFRX) trades 8.4% down after hours on commencing an underwritten public offering of shares; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer actual size, terms have not yet been disclosed.Net proceeds to be used for funding the c...

BARDA awarded ContraFect (CFRX) cost-share contract wherein the company will receive $9.8M in initial funding and up to an additional $77M; shares rallied 20.9% higher after hoursInitial funding will be used to support ContraFect’s ongoing pivotal Phase 3 DISRUPT (Direct Lysis of&...

BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections Results from the Phase 3 DISRUPT study interim futility analysis anticipated in H2 2021 Phase 3 DISRUPT study has ...

ContraFect failed to show superiority in its Phase 2 trial. The company hopes Exebacase can show significant improvements for patients diagnosed with MRSA. Many risks lay ahead and ContraFect is still no more than a speculative investment. For further details see: Contra...